Generex Biotechnology Corporatio (GNBT) 0.0092 $GNBT
Generex Announces Agreement to Acquire Equity Interest in Alfa Rhythm Ltd.
CNW Group - Tue Oct 06, 8:30AM CDT
A unique opportunity for GNBT to expand the scope of its business
Hema Diagnostic Systems in Discussions for Equity Investment by Generex Biotechnology Corp.
ACCESSWIRE - Thu Oct 01, 11:44AM CDT
HEMA DIAGNOSTIC SYSTEMS Announces the Execution of A Non-Binding Letter Of Intent with Generex Biotechnology Corporation. HDS And Generex Will Work Together To Bring Technologies Developed By Both Companies Together By Incorporating The New And Novel Rapid Diagnostic Test Systems For Worldwide Market Expansion
Generex Announces Issuance of Buccal Cannabis White Paper
PR Newswire - Thu Oct 01, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced the issuance of a white paper on the use of cannabis for medicinal purposes and the joint venture between Generex and CannScience Innovations Inc. (www.cannsci.com) for the design and development of products for the delivery of cannabinoids and cannabinoid-derived formulations into the human body via the buccal mucosa (the inner lining of the mouth).
Generex to purchase 51% equity interest in Hema Diagnostic Systems
M2 - Thu Oct 01, 4:01AM CDT
Drug delivery company Generex Biotechnology (Other OTC:GNBT) disclosed on Wednesday that it has signed a non-binding Letter of Intent (LOI) with Hema Diagnostic Systems (HDS), a Florida company that designs and manufactures proprietary infectious disease detection technologies.
Generex Announces Agreement to Acquire Equity Interest in Hema Diagnostic Systems
CNW Group - Wed Sep 30, 8:30AM CDT
Generex seeks to augment the Antigen Express work In infectious diseases with the HDS detection technologies
European Insulin Market 2015-2019 - Increase in Prevalence of Diabetes with Elli Lilly, Novo Nordisk & Sanofi Dominating the Market
M2 - Mon Sep 21, 10:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tnzhlt/insulin_market_in) has announced the addition of the "Insulin Market in Europe 2015-2019" report to their offering. The insulin market in Europe to grow at a CAGR of 6.50% over the period 2014-2019. The report, Insulin Market in Europe 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the insulin market in Europe and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. Growing public awareness of diabetes and the available treatments will likely increase the number of people opting for these treatments. Healthcare companies are organizing awareness camps and discussions to educate people about the condition. These are conducted either alone or in combination with other national institutes. According to the report, changing lifestyle, consumption of high-fat-containing foods, and reduced physical activity increase the prevalence of obesity among the population. Obesity affects the body's normal metabolism, triggering the adipose tissues to release increased amounts of fatty acids, hormones, pro-inflammatory cytokines, and other factors, which are involved in insulin resistance. Further, the report states that the development and regulatory approval of biologic insulin and insulin analog products take longer than small molecules. Minor alterations in the physical structure and chemical pattern can significantly alter the safety and efficacy of these moieties. Unnoticeable variations in the design and execution of a manufacturing process can alter the pharmacokinetic and pharmacodynamics profiles of a drug. Key vendors - Elli Lilly - Novo Nordisk - Sanofi Other prominent vendors - Biodel - Boehringer Ingelheim - Bristol-Myers Squibb - Diamyd Medical - DiaVacs - Generex Biotechnology - Lexicon Pharmaceuticals - Macrogenics - Merck - Osiris Therapeutics - Pfizer - Tolerion - XOMA Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Insulin: An Overview - Market Landscape - Market Segmentation by Type - Buying Criteria - Market Growth Drivers - Drivers and Their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and Their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/tn..._market_in
NVO: 54.61 (-0.12), LXRX: 11.59 (-0.05), MRK: 50.95 (-0.07), OSIR: 16.97 (+0.31), BMY: 61.44 (+0.93)
Thrombosis - Pipeline Review, H1 2015
M2 - Thu Sep 10, 4:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m4rbgj/thrombosis) has announced the addition of the "Thrombosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombosis and special features on late-stage and discontinued projects. the report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Archemix - Arena Pharmaceuticals - Armetheon. - Arrowhead Research - Astellas Pharma - AstraZeneca - Bayer - Bristol-Myers Squibb Company - Cardax Pharmaceuticals - Cereno Scientific - China Biologic Products - CSL - Daewoong Pharmaceutical - Daiichi Sankyo - Eisai - F. Hoffmann-La Roche - Gamma Therapeutics - Generex Biotechnology - GlycoMimetics - Green Cross - IMMD - Isis Pharmaceuticals - Johnson & Johnson - Laboratorios Farmaceuticos Rovi - LG Life Sciences - Lipicard Technologies - Merrion Pharmaceuticals - Nostrum Pharmaceuticals - Pfizer - PLx Pharma - Portola Pharmaceuticals - Prothix BV - Sagene Pharmaceuticals - Sanofi - SciFluor Life Sciences - Tobira Therapeutics. - Zedira For more information visit http://www.researchandmarkets.com/research/m4rbgj/thrombosis
CBPO: 97.22 (+2.50), JNJ: 95.37 (+0.29), PTLA: 43.31 (+0.76), ISIS: 43.24 (+0.86), BMY: 61.44 (+0.93), TBRA: 10.56 (-0.63), ARNA: 2.19 (+0.14)
Generex commences Buccal Leuprolide R&D Work in endocrine disorders
M2 - Wed Sep 09, 5:35AM CDT
Drug delivery company Generex Biotechnology (Other OTC:GNBT) revealed on Tuesday the start of research and development work on buccal Leuprolide under a prior Memorandum of Understanding with NHTherapeutics.
Generex Announces Commencement of Buccal Leuprolide R&D Work
CNW Group - Tue Sep 08, 8:30AM CDT
Collaboration with NHTherapeutics has begun
Generex Provides Update on Success of Buccal Insulin Formulation Enhancement Project
PR Newswire - Tue Aug 25, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today provided an update on the status of the buccal insulin formulation enhancement project for the Company's proprietary Generex Oral-lyn(TM) buccal insulin spray product. As previously announced, Generex engaged the University of Toronto's Center for Molecular Design and Pre-formulations (CMDP) (www.cmdp.uhnres.utoronto.ca) through the University Health Network (www.uhn.ca) with the goal of enhancing the Generex Oral-lyn(TM) formulation to make it more attractive to patients and prospective commercialization partners by increasing the bioavailability of insulin in the product and reducing the number of sprays required to achieve effective prandial metabolic control for patients with diabetes. The project moved forward under the supervision of Dr. David Brusegard, Ph.D., the Company's Chief Operating Officer, Dr. James H. Anderson, Jr., MD, the Company's Senior Scientific Advisor, and Generex consultant Dr. Lakshmi P. Kotra, B. Pharm.(Hons), Ph.D., of CMDP.
Diabetes, Metabolic Syndrome and Cardiovascular Disease - 2015 Global Study
M2 - Wed Jul 22, 9:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8qn9zj/diabetes) has announced the addition of the "Diabetes, Metabolic Syndrome and Cardiovascular Disease" report to their offering. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease - sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes - the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This publications report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles - 30 of the 65 Companies - A. Menarini - Abbott Laboratories - Abbvie - Amgen - Amylin Pharmaceuticals (bought by Bristol-Myers Squibb) - Animas (part of Johnson & Johnson) - Asante - Astellas Pharma, Inc. - AstraZeneca PLC - Bayer - Becton, Dickinson and Company - Biocon - Biodel - BodyMedia - Boehringer Ingelheim - Bristol Myers Squibb - Debiotech - DexCom - Echo Therapeutics, Inc. - Eli Lilly - FIFTY50 Medical, Inc. - Flamel Technologies - Generex Biotechnology Corporation - Lexicon Pharmaceuticals - MannKind Corporation - Medipacs - Medtronic - Merck & Company, Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis For more information visit http://www.researchandmarkets.com/research/8qn9zj/diabetes
ABT: 41.89 (+0.73), MDT: 72.60 (+0.55), LXRX: 11.59 (-0.05), AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37), ECTE: 1.72 (+0.01), JNJ: 95.37 (+0.29), AZN: 32.23 (-0.16), MRK: 50.95 (-0.07), NVS: 91.90 (-0.71)
Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v8vnnk/deep_vein) has announced the addition of the "Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Deep Vein Thrombosis (DVT), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Deep Vein Thrombosis (DVT) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Bayer AG - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Generex Biotechnology Corporation - Laboratorios Farmaceuticos Rovi, S.A. - Merrion Pharmaceuticals Plc - Tobira Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/v8vnnk/deep_vein
BMY: 61.44 (+0.93), TBRA: 10.56 (-0.63)
Generex Announces Capital Investment
CNW Group - Wed Jun 24, 3:01PM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced that it entered into a securities purchase agreement with an institutional investor on June 24, 2015. The investor has agreed to purchase in a private placement an aggregate of 500 shares of the Company's newly designated non-voting Series G 9% Convertible Preferred Stock ("convertible preferred stock"
and warrants to purchase up to an aggregate of 100% of the shares of its common stock issuable upon conversion of the convertible preferred stock ("warrants" at the closing. The convertible preferred stock and warrants will be sold in units, with each unit consisting of one share of convertible preferred stock and a warrant to purchase 100% of the shares of the Company's common stock issuable upon conversion of such shares of convertible preferred stock. Each unit will be sold at a negotiated price of $1,000 for an aggregate purchase price of $500,000. An aggregate of 66,666,666 shares of the Company's common stock will be issuable upon conversion of, or exercise of, the convertible preferred stock and warrants issued at the closing. In addition, until the one year anniversary of the date upon which the Company's stockholders approve an increase in the Company's authorized capital, the investor may, in its sole determination, elect to purchase, in one or more purchases, additional units consisting of convertible preferred stock and warrants at a purchase price of $1,000 per unit with an aggregate subscription amount thereof of up to $500,000, which units will be identical to the units of convertible preferred stock and warrants issued in connection with the initial closing.
Generex Biotechnology Corporation - Product Pipeline Review - 2014
M2 - Mon Jun 08, 7:18AM CDT
Product Pipeline Review - 2014
Generex Announces Agreement to Acquire Equity Interest in Alfa Rhythm Ltd.
CNW Group - Tue Oct 06, 8:30AM CDT
A unique opportunity for GNBT to expand the scope of its business
Hema Diagnostic Systems in Discussions for Equity Investment by Generex Biotechnology Corp.
ACCESSWIRE - Thu Oct 01, 11:44AM CDT
HEMA DIAGNOSTIC SYSTEMS Announces the Execution of A Non-Binding Letter Of Intent with Generex Biotechnology Corporation. HDS And Generex Will Work Together To Bring Technologies Developed By Both Companies Together By Incorporating The New And Novel Rapid Diagnostic Test Systems For Worldwide Market Expansion
Generex Announces Issuance of Buccal Cannabis White Paper
PR Newswire - Thu Oct 01, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced the issuance of a white paper on the use of cannabis for medicinal purposes and the joint venture between Generex and CannScience Innovations Inc. (www.cannsci.com) for the design and development of products for the delivery of cannabinoids and cannabinoid-derived formulations into the human body via the buccal mucosa (the inner lining of the mouth).
Generex to purchase 51% equity interest in Hema Diagnostic Systems
M2 - Thu Oct 01, 4:01AM CDT
Drug delivery company Generex Biotechnology (Other OTC:GNBT) disclosed on Wednesday that it has signed a non-binding Letter of Intent (LOI) with Hema Diagnostic Systems (HDS), a Florida company that designs and manufactures proprietary infectious disease detection technologies.
Generex Announces Agreement to Acquire Equity Interest in Hema Diagnostic Systems
CNW Group - Wed Sep 30, 8:30AM CDT
Generex seeks to augment the Antigen Express work In infectious diseases with the HDS detection technologies
European Insulin Market 2015-2019 - Increase in Prevalence of Diabetes with Elli Lilly, Novo Nordisk & Sanofi Dominating the Market
M2 - Mon Sep 21, 10:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tnzhlt/insulin_market_in) has announced the addition of the "Insulin Market in Europe 2015-2019" report to their offering. The insulin market in Europe to grow at a CAGR of 6.50% over the period 2014-2019. The report, Insulin Market in Europe 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the insulin market in Europe and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. Growing public awareness of diabetes and the available treatments will likely increase the number of people opting for these treatments. Healthcare companies are organizing awareness camps and discussions to educate people about the condition. These are conducted either alone or in combination with other national institutes. According to the report, changing lifestyle, consumption of high-fat-containing foods, and reduced physical activity increase the prevalence of obesity among the population. Obesity affects the body's normal metabolism, triggering the adipose tissues to release increased amounts of fatty acids, hormones, pro-inflammatory cytokines, and other factors, which are involved in insulin resistance. Further, the report states that the development and regulatory approval of biologic insulin and insulin analog products take longer than small molecules. Minor alterations in the physical structure and chemical pattern can significantly alter the safety and efficacy of these moieties. Unnoticeable variations in the design and execution of a manufacturing process can alter the pharmacokinetic and pharmacodynamics profiles of a drug. Key vendors - Elli Lilly - Novo Nordisk - Sanofi Other prominent vendors - Biodel - Boehringer Ingelheim - Bristol-Myers Squibb - Diamyd Medical - DiaVacs - Generex Biotechnology - Lexicon Pharmaceuticals - Macrogenics - Merck - Osiris Therapeutics - Pfizer - Tolerion - XOMA Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Insulin: An Overview - Market Landscape - Market Segmentation by Type - Buying Criteria - Market Growth Drivers - Drivers and Their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and Their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/tn..._market_in
NVO: 54.61 (-0.12), LXRX: 11.59 (-0.05), MRK: 50.95 (-0.07), OSIR: 16.97 (+0.31), BMY: 61.44 (+0.93)
Thrombosis - Pipeline Review, H1 2015
M2 - Thu Sep 10, 4:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m4rbgj/thrombosis) has announced the addition of the "Thrombosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombosis and special features on late-stage and discontinued projects. the report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Archemix - Arena Pharmaceuticals - Armetheon. - Arrowhead Research - Astellas Pharma - AstraZeneca - Bayer - Bristol-Myers Squibb Company - Cardax Pharmaceuticals - Cereno Scientific - China Biologic Products - CSL - Daewoong Pharmaceutical - Daiichi Sankyo - Eisai - F. Hoffmann-La Roche - Gamma Therapeutics - Generex Biotechnology - GlycoMimetics - Green Cross - IMMD - Isis Pharmaceuticals - Johnson & Johnson - Laboratorios Farmaceuticos Rovi - LG Life Sciences - Lipicard Technologies - Merrion Pharmaceuticals - Nostrum Pharmaceuticals - Pfizer - PLx Pharma - Portola Pharmaceuticals - Prothix BV - Sagene Pharmaceuticals - Sanofi - SciFluor Life Sciences - Tobira Therapeutics. - Zedira For more information visit http://www.researchandmarkets.com/research/m4rbgj/thrombosis
CBPO: 97.22 (+2.50), JNJ: 95.37 (+0.29), PTLA: 43.31 (+0.76), ISIS: 43.24 (+0.86), BMY: 61.44 (+0.93), TBRA: 10.56 (-0.63), ARNA: 2.19 (+0.14)
Generex commences Buccal Leuprolide R&D Work in endocrine disorders
M2 - Wed Sep 09, 5:35AM CDT
Drug delivery company Generex Biotechnology (Other OTC:GNBT) revealed on Tuesday the start of research and development work on buccal Leuprolide under a prior Memorandum of Understanding with NHTherapeutics.
Generex Announces Commencement of Buccal Leuprolide R&D Work
CNW Group - Tue Sep 08, 8:30AM CDT
Collaboration with NHTherapeutics has begun
Generex Provides Update on Success of Buccal Insulin Formulation Enhancement Project
PR Newswire - Tue Aug 25, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today provided an update on the status of the buccal insulin formulation enhancement project for the Company's proprietary Generex Oral-lyn(TM) buccal insulin spray product. As previously announced, Generex engaged the University of Toronto's Center for Molecular Design and Pre-formulations (CMDP) (www.cmdp.uhnres.utoronto.ca) through the University Health Network (www.uhn.ca) with the goal of enhancing the Generex Oral-lyn(TM) formulation to make it more attractive to patients and prospective commercialization partners by increasing the bioavailability of insulin in the product and reducing the number of sprays required to achieve effective prandial metabolic control for patients with diabetes. The project moved forward under the supervision of Dr. David Brusegard, Ph.D., the Company's Chief Operating Officer, Dr. James H. Anderson, Jr., MD, the Company's Senior Scientific Advisor, and Generex consultant Dr. Lakshmi P. Kotra, B. Pharm.(Hons), Ph.D., of CMDP.
Diabetes, Metabolic Syndrome and Cardiovascular Disease - 2015 Global Study
M2 - Wed Jul 22, 9:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8qn9zj/diabetes) has announced the addition of the "Diabetes, Metabolic Syndrome and Cardiovascular Disease" report to their offering. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease - sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes - the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This publications report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles - 30 of the 65 Companies - A. Menarini - Abbott Laboratories - Abbvie - Amgen - Amylin Pharmaceuticals (bought by Bristol-Myers Squibb) - Animas (part of Johnson & Johnson) - Asante - Astellas Pharma, Inc. - AstraZeneca PLC - Bayer - Becton, Dickinson and Company - Biocon - Biodel - BodyMedia - Boehringer Ingelheim - Bristol Myers Squibb - Debiotech - DexCom - Echo Therapeutics, Inc. - Eli Lilly - FIFTY50 Medical, Inc. - Flamel Technologies - Generex Biotechnology Corporation - Lexicon Pharmaceuticals - MannKind Corporation - Medipacs - Medtronic - Merck & Company, Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis For more information visit http://www.researchandmarkets.com/research/8qn9zj/diabetes
ABT: 41.89 (+0.73), MDT: 72.60 (+0.55), LXRX: 11.59 (-0.05), AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37), ECTE: 1.72 (+0.01), JNJ: 95.37 (+0.29), AZN: 32.23 (-0.16), MRK: 50.95 (-0.07), NVS: 91.90 (-0.71)
Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v8vnnk/deep_vein) has announced the addition of the "Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Deep Vein Thrombosis (DVT), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Deep Vein Thrombosis (DVT) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Bayer AG - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Generex Biotechnology Corporation - Laboratorios Farmaceuticos Rovi, S.A. - Merrion Pharmaceuticals Plc - Tobira Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/v8vnnk/deep_vein
BMY: 61.44 (+0.93), TBRA: 10.56 (-0.63)
Generex Announces Capital Investment
CNW Group - Wed Jun 24, 3:01PM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced that it entered into a securities purchase agreement with an institutional investor on June 24, 2015. The investor has agreed to purchase in a private placement an aggregate of 500 shares of the Company's newly designated non-voting Series G 9% Convertible Preferred Stock ("convertible preferred stock"
and warrants to purchase up to an aggregate of 100% of the shares of its common stock issuable upon conversion of the convertible preferred stock ("warrants" at the closing. The convertible preferred stock and warrants will be sold in units, with each unit consisting of one share of convertible preferred stock and a warrant to purchase 100% of the shares of the Company's common stock issuable upon conversion of such shares of convertible preferred stock. Each unit will be sold at a negotiated price of $1,000 for an aggregate purchase price of $500,000. An aggregate of 66,666,666 shares of the Company's common stock will be issuable upon conversion of, or exercise of, the convertible preferred stock and warrants issued at the closing. In addition, until the one year anniversary of the date upon which the Company's stockholders approve an increase in the Company's authorized capital, the investor may, in its sole determination, elect to purchase, in one or more purchases, additional units consisting of convertible preferred stock and warrants at a purchase price of $1,000 per unit with an aggregate subscription amount thereof of up to $500,000, which units will be identical to the units of convertible preferred stock and warrants issued in connection with the initial closing. Generex Biotechnology Corporation - Product Pipeline Review - 2014
M2 - Mon Jun 08, 7:18AM CDT
Product Pipeline Review - 2014
